99% Purity Edoxaban Powder Edoxaban Material Pharmaceutical Edoxaban

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung-Edoxaban
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Edoxaban
• Name: Edoxaban Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC UV
• Shelf Life: 2 Years
• CAS No.: 480449-70-5
• Mf: C24h30cln7o4s
• MW: 548.06
• Density: 1.43
• Storage: Cool and Dry
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

99% Purity Edoxaban powder Edoxaban Material Pharmaceutical Edoxaban 

Product Description

Product Details

Product name	Edoxaban
Cas number	480449-70-5
Appearance	White powder
MF	C24H30ClN7O4S
MW	548.06

Edoxaban (tosylate Monohydrate) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Edoxaban (tosylate Monohydrate) was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. Edoxaban (tosylate Monohydrate) was also approved by the FDA in January 2015 for the prevention of stroke and non-central-nervous-system systemic embolism.

Application&Function

Function of Edoxaban (tosylate Monohydrate)
1.Edoxaban (tosylate Monohydrate) is used for Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
2. Limitations of use
Edoxaban (tosylate Monohydrate) should not be used in nonvalvular atrial fibrillation (NVAF) patients with a creatinine clearance (CrCl) greater than 95 mL/minute.
Application of Edoxaban (tosylate Monohydrate)

1.Edoxaban (tosylate Monohydrate) is used for Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
2. Limitations of use
 Edoxaban (tosylate Monohydrate) should not be used in nonvalvular atrial fibrillation (NVAF) patients with a creatinine  clearance (CrCl) greater than 95 mL/minute.

Specification